Ocular Therapeutix, Inc. (OCUL) key performance indicators and operating metrics (1 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Dextenza End-User Unit Sales Growth | 9.70 percent | FY2025-Q3 |
Back to OCUL overview · OCUL earnings · OCUL holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.